A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment

BACKGROUND AND OBJECTIVES: In 10% to 20% of cases, Kawasaki disease is refractory to intravenous immunoglobulin (IVIg), an expensive medication under a national shortage. Data suggest that infliximab is a viable alternative to a second dose of IVIg, with similar efficacy and safety. We compared the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Hosp Pediatr
Autores principales: Johnson, Scarlett Carmen, Williams, Daniel Clay, Brinton, Daniel, Chew, Marshall, Simpson, Annie, Andrews, Annie Lintzenich
Formato: Artigo
Lenguaje:Inglês
Publicado: American Academy of Pediatrics 2021
Materias:
Brief Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769204/
https://ncbi.nlm.nih.gov/pubmed/33293266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1542/hpeds.2020-0188
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares